Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Fedratinib in Combination With Decitabine in Patients With Myeloproliferative Neoplasms in Accelerated and Blast Phase

NCT05524857 is registered in ClinicalTrials.gov with Joseph Jurcic as lead sponsor.

NCT NCT05524857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05524857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Fedratinib in Combination With Decitabine in Patients With Myeloproliferative Neoplasms in Accelerated and Blast Phase
Lead sponsor
Joseph Jurcic
Phase
Phase 1
Overall status
Terminated
Start date
January 28, 2022
Completion date
April 9, 2024
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myeloproliferative neoplasm